Results 61 to 70 of about 21,607 (116)

Immunomodulatory Effects of Tigecycline in Balb/C Mice

Acta Pharmaceutica, 2018
Tigecycline is a glycylcycline antibiotic approved by the FDA for the treatment of complicated infections. Despite its effectiveness, the FDA announced a warning of increasing mortality associated with its use. There is, however, no clear explanation for
Elhayek Shada Y., Fararjeh Mohammad A., Assaf Areej M., Abu-Rish Eman Y., Bustanji Yasser   +4 more
doaj   +1 more source

Tigecycline-amikacin combination effectively suppresses the selection of resistance in clinical isolates of KPC-producing Klebsiella pneumoniae

Frontiers in Microbiology, 2016
By far, only tigecycline, colistin and some aminoglycosides still show favorable in vitro activities against carbapenem-resistant Enterobacteriaceae. However, rapid emergence of resistance often occurs during long-term treatment in clinic, challenging ...
Wentao Ni, Chuanqi Wei, Chufei Zhou, Jin Zhao, Beibei Liang, Junchang Cui, Rui Wang, Youning Liu   +7 more
doaj   +1 more source

Tigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremia

International Journal of Infectious Diseases, 2017
The successful use of tigecycline in a 12-month old liver transplant recipient with extensively drug-resistant Acinetobacter baumannii bacteremia is presented.
Jiawei Zeng, Lidan Zhang, Min Gao, Jingjing Wu, Haiyan Wu, Jie Chen, Xiao Chen, Wen Tang   +7 more
doaj   +1 more source

Structural basis for differential inhibition of eukaryotic ribosomes by tigecycline

Nature Communications
Tigecycline is widely used for treating complicated bacterial infections for which there are no effective drugs. It inhibits bacterial protein translation by blocking the ribosomal A-site.
Xiang Li, Mengjiao Wang, Timo Denk, Robert Buschauer, Yi Li, Roland Beckmann, Jingdong Cheng   +6 more
doaj   +1 more source

Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii

BMC Pharmacology and Toxicology, 2019
Background Tigecycline, with broad in vitro antibacterial activity, has been widely used off-label for nosocomial pneumonia caused by multi-drug resistant Acinetobacter baumannii (MDRAB).
Yangang Zhou, Xumin Chen, Ping Xu, Yan Zhu, Kuangguo Wang, Daxiong Xiang, Feng Wang, Hoan Linh Banh   +7 more
doaj   +1 more source

Clinical and microbiological analysis of risk factors for breakthrough bloodstream infection during Tigecycline Therapy

Scientific Reports
Background Tigecycline is widely used to treat a variety of bacterial infections despite concerns regarding increased mortality in severe infections.
Sol Jin, So Yun Lim, Yun Woo Lee, Heungsup Sung, Mi-Na Kim, Seongman Bae, Jiwon Jung, Min Jae Kim, Sung-Han Kim, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Eun Hee Song, Yong Pil Chong   +13 more
doaj   +1 more source

A promising metabolite, 9-aminominocycline, restores the sensitivity of tigecycline against tet(X4)-positive Escherichia coli

Frontiers in Microbiology
The emergence and widespread of tigecycline resistance undoubtedly poses a serious threat to public health globally. The exploration of combination therapies has become preferred antibacterial strategies to alleviate this global burden.
Feifei Sun, Feifei Sun, Lin Zhang, Xuan Ma, Tariq Ali, Yongning Wu, Lin Li   +6 more
doaj   +1 more source

The first tigecycline resistant Enterococcus faecium in Norway was related to tigecycline exposure

Journal of Global Antimicrobial Resistance
: Objectives: We describe the first tigecycline resistant enterococcal isolate in Norway and the mechanisms involved. Material and methods: The Norwegian National Advisory Unit on Detection of Antimicrobial Resistance (K-res).
Kristin Hegstad, Anna K. Pöntinen, Jørgen V. Bjørnholt, Else Quist-Paulsen, Arnfinn Sundsfjord   +4 more
doaj   +1 more source

Comparative Genomic Analysis of Tigecycline Resistance Development in Clinical Acinetobacter baumannii Isolates

Infection and Drug Resistance
Xiaoxia Li,1,* Junnian Liu,2,* Xinyu Zhang,1 Juan Li,3 Luhan Xuan,1 Sue Yuan,1 Jianglin Li,1 Yu Sun,1 Xuefei Du1 1Clinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of
Li X, Liu J, Zhang X, Li J, Xuan L, Yuan S, Li J, Sun Y, Du X   +8 more
doaj  

Incidence and characteristics of eravacycline-associated increase in serum bilirubin levels: a retrospective study. [PDF]

Front Pharmacol
Si Y, Chen M, Zhang J, Jiang J, Zhang Y, Yu G, Guo N, Yan G, Leng B.   +8 more
europepmc   +1 more source